Healthcare Global Enterprises Ltd vs Pramodini Medicare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Healthcare Global Enterprises Ltd is ₹ 550.15 as of 23 Oct 15:30 . The P/E Ratio of Healthcare Global Enterprises Ltd changed from 69.7 on March 2022 to 570.3 on March 2026 . This represents a CAGR of 52.26% over 5 yearsThe P/E Ratio of Pramodini Medicare Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 years The Market Cap of Healthcare Global Enterprises Ltd changed from ₹ 2394 crore on March 2021 to ₹ 7833 crore on March 2026 . This represents a CAGR of 21.84% over 6 yearsThe Market Cap of Pramodini Medicare Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 years The revenue of Healthcare Global Enterprises Ltd for the Jun '26 is ₹ 708.16 crore as compare to the Mar '26 revenue of ₹ 665.92 crore. This represent the growth of 6.34% The revenue of Pramodini Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Healthcare Global Enterprises Ltd for the Jun '26 is ₹ 135.32 crore as compare to the Mar '26 ebitda of ₹ 106.76 crore. This represent the growth of 26.75% The ebitda of Pramodini Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Healthcare Global Enterprises Ltd changed from ₹ 13.63 crore to ₹ 16.46 crore over 9 quarters. This represents a CAGR of 8.75% The net profit of Pramodini Medicare Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The Dividend Payout of Healthcare Global Enterprises Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Pramodini Medicare Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Healthcare Global Enterprises Ltd

Healthcare Global Enterprises Limited was originally incorporated as Curie Centre of Oncology Private Limited on March 12, 1998 at Bengaluru, Karnataka, India as a Private Limited Company.
The name of the Company was changed to HealthCare Global Enterprises Private Limited on November 14, 2005.
Thereafter, it was converted into a Public Limited Company and the name of the Company was changed to Healthcare Global Enterprises Limited on July 5, 2006. Presently, the Company is engaged in setting up and managing hospitals and medical diagnostic services including scientific testing and consultancy services in the pharmaceutical and medical sector.
Under the 'HCG' brand, the Company operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed by the AERB.

About Pramodini Medicare Ltd

Pramodini Medicare Limited was originally incorporated on September 12, 2000 as 'Pramodini Medicare Private Limited' with the Registrar of Companies, Andhra Pradesh.
Thereafter, the status of the Company changed to public limited Company and the name was changed to 'Pramodini Medicare Limited' vide fresh certificate of incorporation dated November 12, 2025. Company was originally incorporated in the year 2000 with the objective to provide diagnostic services.
The Company provide a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India. Diagnostic services include a comprehensive range of offerings: (i) 'Radiology' which covers Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), X- ray, Ultrasound with colour doppler, Mammography, DEXA Scan and Intervention Radiology, (ii) 'Clinical Laboratory' which includes Haematology, Micro-Biology, Immunology, Pathology & Bio-Chemistry and (iii) 'Nuclear Medicine' which includes PET-CT (Positron Emission Tomography-Computed Tomography), SPECT (Single Photon Emission Computed Tomography) and Nuclear therapy.

FAQs for the comparison of Healthcare Global Enterprises Ltd and null

Which company has a larger market capitalization, Healthcare Global Enterprises Ltd or Pramodini Medicare Ltd?

Market cap of Healthcare Global Enterprises Ltd is 8,213 Cr while Market cap of Pramodini Medicare Ltd is 239 Cr

What are the key factors driving the stock performance of Healthcare Global Enterprises Ltd and Pramodini Medicare Ltd?

The stock performance of Healthcare Global Enterprises Ltd and Pramodini Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Healthcare Global Enterprises Ltd and Pramodini Medicare Ltd?

As of October 25, 2026, the Healthcare Global Enterprises Ltd stock price is INR ₹550.15. On the other hand, Pramodini Medicare Ltd stock price is INR ₹108.65.

How do dividend payouts of Healthcare Global Enterprises Ltd and Pramodini Medicare Ltd compare?

To compare the dividend payouts of Healthcare Global Enterprises Ltd and Pramodini Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.